Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.Eur J Contracept Reprod Health Care. 2010; 15: 314-325
- Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy.Drugs. 2010; 70: 541-559
- An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells.J Steroid Biochem Mol Biol. 2003; 87: 111-122
- Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey.Contraception. 2011; 84: 199-204
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.Eur J Contracept Reprod Health Care. 2011; 16: 444-457
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.Eur J Contracept Reprod Health Care. 2011; 16: 458-467
- Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study.Eur J Contracept Reprod Health Care. 2011; 16: 76-84
- Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study.Hum Reprod. 2011; 26: 1338-1347
- Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.Thromb Haemost. 2011; 105: 560-567
- Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.Eur J Contracept Reprod Health Care. 2011; 16: 430-443
- Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol in comparison to levonorgestrel/ethinylestradiol.Acta Obstet Gynecol Scand. 2012; 91: 1279-1285
- Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.Obstet Gynecol. 2012; 119: 989-999
- Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).Contraception. 2007; 75: 16-22
- Menstrual bleeding expectations and short-term contraception discontinuation in Mexico.Stud Fam Plann. 1983; 14: 127-133
- Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.Contraception. 2013; 87: 193-200
- Changing convention in combination oral contraceptives: estradiol and nomegestrol acetate in a monophasic 24/4 regimen.J Fam Plann Reprod Health Care. 2013; 39: 211-216
- Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.Clin Drug Investig. 2011; 31: 519-525
- Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.Obstet Gynecol. 2009; 114: 1205-1212
- Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.Contraception. 2004; 70: 359-363
- Amenorrhea associated with contraception-an international study on acceptability.Contraception. 2003; 67: 1-8
- Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use.Contraception. 1999; 59: 357-362
☆Role of the Funding Source: Financial support for the conduct of the research and the preparation of this article was provided by Merck & Co., Inc., Kenilworth, NJ, USA. The sponsor was involved in study design; in the collection, analysis and interpretation of data from the original studies; and in providing data for the present analysis.
☆☆Clinical trial registration numbers: NCT00413062 and NCT00511199.
★Conflicts of Interest: Dr. Mansour has received financial support to attend pharmaceutical advisory board meetings, undertake research studies, and to speak at educational meetings and conferences from Astellas, Bayer, Consilient Healthcare, HRA Pharma, Merck & Co., Inc., Pfizer, and Vifor Pharma. Dr. Korver is a former employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, and currently provides consultancy services to the company. Dr. Kher is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. Dr. Westhoff is a DSMB member for FDA- and EMA-mandated post-approval safety studies sponsored by Bayer and Merck, including post-approval safety studies of both NOMAC/E2 and drospirenone oral contraceptives.